Profile Development Stages and Performance Criteria (Mr. O’Donnell)

- Feedback was received at the f2f Steering Committee Meeting on January 27 in Chicago
- Stage 3, “Technically Confirmed,” will focus on practical confirmation of the Profile (i.e., feasibility):
  - Denotes that Profile text is understandable and steps are implementable
  - Not yet concerned with confirming the Claim
  - All Profile procedures and details have been implemented on at least two vendor platforms and at two or more sites:

- There was discussion regarding what documentation around the Technically-Confirmed process would be required
  - BC as “gate keeper,” responsible for Profile stage approval
  - BC coordinates feasibility trials with a minimum of two sites
  - BC decides how a sites’ conformance might be audited

- Stage 3, “Technically Confirmed,” must clearly state that the Claim is to be confirmed at Stage 4, which may not be within the scope of QIBA

- Stage 4, “Claim Confirmed,” entails:
  - Evaluating and measuring performance against the Claim
  - Conformant deployments can achieve the Profile Claim
  - Some Claims might be confirmable with phantoms/DROs but likely measurement of performance in phantoms/DRO is not sufficient by itself to declare patient-oriented Claims to be confirmed

- Stage 5, “Clinically Confirmed,” involves:
  - Collecting data broadly in the field on patients that will confirm the Claim
  - The Profile Claim has been achieved in a clinical setting

- The semantics of Stage 5, “Clinically Confirmed” and the criteria of this level are still under discussion (QIBA won’t accomplish this stage, but may act as facilitator/enabler to assist)
Mr. O’Donnell to send the following to RSNA staff to post on the QIBA wiki at:
  o Updated Profile Template (January 2016)
  o Updated Claims Guidance (February 2016)
  o Profile Stage Descriptions (February 2016)

Claim Guidance (Mr. O’Donnell)
  o A progress update was provided
  o Recommendations were made regarding additional changes to this document

Next Call: Wednesday, February 24 at 3 PM CT